Skip to main content
No. of Recommendations: 4
Hi Mark:

Thanks for posting the information on VRTX and ELN, both look very good for inclusion in KARB and KARM respectively.

Don't worry, and don't be confused, biotech does not fit into the RB, RM or GG criteria well at all, but we can use elements of those investing philosophies to help us decide whether or not biotechs are good investments.

Biotechs and pharmas never can get sustained advantage, they get that government-allowed monopoly through patent protection. As you know the FDA can giveth and the FDA can also taketh away.

What we want in a biotech are some current products or ones in phase III trials, a very strong pipeline, excellent management, strong R&D spending compared to revenues, and products that are targeted to as big a market as possible. A cure for obesity or the common cold would be great!

Thanks for taking the time to repost your great research here.



Here are some resources I posted in preparation for the biotech seminar, and then later for the biotech seminar grads board.

Biotech TMF Links

Zeke Ashton's Foolish Biotech Investment Checklist
1. Successful products on the market
2. A deep product pipeline with late-stage candidates
3. Drugs and candidates that target large or underserved markets
4. Partnerships and marketing agreements with blue-chip drug manufacturers
5. Research & development spending
6. Enough cash to fund operations for two years
7. Experienced management
8. Favorable Foolish financial analysis

Zeke Ashton's Foolish Biotech Investment Checklist Articles
Part I
Part II
Part III
FOOL ON THE HILL: An Investment Opinion
When the FDA Says No
Shareholders of fledgling biotech drug maker Cell Pathways watched the stock collapse this week when the FDA rejected the company's application to market cancer drug Aptosyn. Investors who examined the depth of the company's drug candidate pipeline, and whether it had cash or alliances with big drug makers to survive hard knocks, would have known the risks.
By Tom Jacobs (TMF Tom9)
September 29, 2000

To invest in a drug company, you need to know two things at a minimum:

1. Does the company have enough drug candidates in its pipeline to compensate for clinical failure or FDA rejection of one or more?

2. If currently unprofitable, does the company have enough cash and big drug maker partners to survive bad news?

Biotechnology Crash Course by Zeke Ashton (TMF Centaur)
July 18, 2000
For those interested in getting up-to-speed as quickly as possible, here are some books, magazine articles, and research documents that offer excellent information for individual investors.

Rule Breaker:

Tissue Engineering

Lancet Tissue Engineering Review

Finding Biotech Rule Breakers

HGSI Breakdown

MLNM Breakdown

RB Biotech Investing Chat

MLNM CEO interview

HGSI CEO interview

CRA President interview

RB CRA Buy Report

RB AMGN Buy Report
AMGN RB update 6/00

Biotech Education

R&D a Key to Biotech

FOTH Investing in biotech

Biotech Bubble? By Tom Jacobs (TMF Tom9)
August 25, 2000

Amgen (AMGN)
By Zeke Ashton (TMF Centaur)

U.S. OKs Human Embryo Research By Tom Jacobs (TMF Tom9)
August 23, 2000

Myriad Genetics Reports By Tom Jacobs (TMF Tom9)
August 22, 2000

Biogen Widens Pipeline By Tom Jacobs (TMF Tom9)
August 18, 2000

Geron Reports By Tom Jacobs (TMF Tom9)
August 15, 2000

Ways to Invest in Biotech by Jeff Fischer (TMF Jeff)
July 5, 2000

Corning Muscles in on DNA Chips By Tom Jacobs (TMF Tom9)
September 14, 2000

Human Genome, Genzyme Buy Smart By Tom Jacobs (TMF Tom9)
September 11, 2000

Lilly Trades Biotech Deals By Tom Jacobs (TMF Tom9)
September 6, 2000

Amgen Blood Feud Nears End By Tom Jacobs (TMF Tom9)
September 5, 2000

Biotechnology Web Sites


Distributed on-line community supporting the life sciences

The Consumer Guide for the Life Scientist

Insight for the biotech industry

BioInformatics, Inc.
Websites for Biomedical Marketing Professionals

Jobs, corporate profiles & more ...

Analyses, interpretations, news, company developments, commentaries

Global hubsite for the like sciences

Biotechnology corporate intelligence products and services

Worldwide Biotechnology news and information source

Integrated genomics portal

Genetic Engineering News
Bioindustry News Publication

Your "Retriever" for Sector & Investment Information

Represents the country's leading research-based pharmaceutical
and biotechnology companies

Recombinant Capital
The online magazine of biotechnology industry analysis

The Scientist
The News Journal for the Life Scientist

Trends in Biotechnology
Extensive resource of key life science journals

Yahoo Biotechnology News
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.